AI assistant
Tempest Therapeutics, Inc. — Director's Dealing 2021
Jul 7, 2021
34632_dirs_2021-07-06_03fb1c4c-bf79-4b47-ba3b-4039689433de.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Tempest Therapeutics, Inc. (TPST)
CIK: 0001544227
Period of Report: 2021-07-01
Reporting Person: Xu Stella (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-01 | Stock Option (Right to Buy) | $11.07 | A | 6635 | Acquired | 2031-06-30 | Common Stock (6635) | Direct |
Footnotes
F1: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service.
F2: The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is a manager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.